Study of Hepatitis C Treatment With Glecaprevir-Pibrentasvir in Pregnant Women With Past or Current Drug Use

What this Trial Is About

This research focuses on pregnant adults aged 18 and older who have hepatitis C virus infection and a history of past or current drug use. It aims to evaluate how well pregnant women can adhere to and complete treatment with glecaprevir-pibrentasvir during pregnancy, as well as to understand their experiences with hepatitis C treatment during this time. Participants will receive glecaprevir-pibrentasvir, taken orally once daily for 56 days. The study includes four in-person visits the first to provide treatment information and perform tests including HIV, HBV, and cirrhosis assessment the second during treatment to assess medication adherence and viral load the third at treatment completion to repeat these assessments and a final visit four weeks after treatment ends for viral load testing. Additional clinical information and maternal and fetal outcomes will be collected from medical records up to one year after enrollment. Throughout the study, participants will undergo standard laboratory tests such as HCV RNA, complete blood count, and metabolic panel. Researchers will monitor medication adherence, treatment completion rates, patient satisfaction, virologic response, and clinical success. Maternal and fetal health outcomes and any hepatitis C reinfections will be followed through medical records for one year, with the total participation lasting about one year.

Feasibility and Acceptability of HCV Treatment in Pregnancy